|
Welcome to datamethods
|
|
2
|
3821
|
July 24, 2018
|
|
Ethics of Rushing COVID19 Risk Prediction Models
|
|
23
|
3871
|
May 29, 2020
|
|
Residuals of high resolution calibrations curves
|
|
3
|
102
|
May 29, 2020
|
|
Surgisphere covid data - possible explanations for puzzling data?
|
|
2
|
99
|
May 29, 2020
|
|
Who should define reasonable priors and how?
|
|
16
|
1372
|
May 29, 2020
|
|
Modeling for Observational Treatment Comparisons
|
|
1
|
76
|
May 29, 2020
|
|
When is censoring too high?
|
|
12
|
2674
|
May 28, 2020
|
|
Reference Collection to push back against "Common Statistical Myths"
|
|
36
|
23232
|
May 28, 2020
|
|
More on the sad state of fraud detection
|
|
1
|
72
|
May 27, 2020
|
|
BBR Session 5: One- and Two-Sample Methods for Means and One-Sample Methods for Proportions
|
|
19
|
1449
|
May 25, 2020
|
|
Does lower residual values decrease the coefficient of determination?
|
|
1
|
59
|
May 24, 2020
|
|
"Exchangeability" in observational studies versus RCTs
|
|
3
|
318
|
May 24, 2020
|
|
Calculate ratio and confidence interval for two hazard ratios
|
|
6
|
160
|
May 23, 2020
|
|
RMS Discussions
|
|
49
|
1245
|
May 23, 2020
|
|
Disentagling modeling choice of Categorical Covariates vs Hierarchical Modeling
|
|
3
|
123
|
May 23, 2020
|
|
Fully sequential Bayesian clinical trial design for in-hospital treatment of COVID-19
|
|
23
|
2141
|
May 23, 2020
|
|
Best approach to comparing time-of-day effects for binary event (admission to hospital)
|
|
9
|
340
|
May 23, 2020
|
|
When Should Clinicians Act on Non–Statistically Significant Results From Clinical Trials?
|
|
7
|
655
|
May 21, 2020
|
|
An example of what we're dealing with here
|
|
1
|
101
|
May 20, 2020
|
|
Feedback on diagnostic 'game'
|
|
1
|
90
|
May 20, 2020
|
|
First RCT of Lopinavir–Ritonavir on SARS-CoV2
|
|
38
|
3937
|
May 19, 2020
|
|
Considerations about coefficient of variation in clinical practice
|
|
2
|
127
|
May 20, 2020
|
|
Investigate parallel observational cohort or leave alone?
|
|
1
|
90
|
May 18, 2020
|
|
Does the Table 2 Fallacy apply in this NEJM paper?
|
|
11
|
861
|
May 15, 2020
|
|
Open-label RCT of triple combination (LPV/r, Ribavirin, Interferon) on SARS-CoV2
|
|
2
|
352
|
May 15, 2020
|
|
Propensity score matching while doing Survey Analysis with National Inpatient Sample
|
|
5
|
244
|
May 15, 2020
|
|
Random vs. stratified sampling in estimating a varying treatment effect
|
|
1
|
107
|
May 14, 2020
|
|
Reading list for an article about how modern "fraud detection" methods are deeply flawed
|
|
2
|
177
|
May 13, 2020
|
|
Confidence limit index/ratio as an additional measure of precision?
|
|
7
|
240
|
May 13, 2020
|
|
Post-Hoc Assumption Tests
|
|
2
|
163
|
May 13, 2020
|
